Profile data is unavailable for this security.
About the company
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
- Revenue in USD (TTM)35.24m
- Net income in USD-13.51m
- Incorporated2015
- Employees85.00
- LocationBiofrontera Inc120 Presidential Way,, Suite 330WOBURN 01801United StatesUSA
- Phone+1 (781) 245-1325
- Fax+1 (302) 655-5049
- Websitehttps://www.biofrontera-us.com/